Simultaneous modulated accelerated radiation therapy in the treatment of nasopharyngeal cancer: A local center’s experience

Wu, Shixiu; Xie, Congying; Jin, Xiance; Zhang, Ping

doi:10.1016/j.ijrobp.2005.12.041

Cited by 42 publications

(45 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The doses prescribed to gross target volume (GTV) and clinical target volume (CTV) were 2.5 and 2.0 Gy per fraction with a total dose of 70 and 60 Gy delivered in 28 fractions within 6 weeks, respectively. The delineation of GTV, CTV and dose-volume constraints of normal tissue was presented in our previous report (15). All patients received IMRT as definitive treatment without concurrent chemotherapy.…”

Section: Patient Selectionmentioning

confidence: 99%

XRCC3 Polymorphisms are Associated with the Risk of Developing Radiation-induced Late Xerostomia in Nasopharyngeal Carcinoma Patients Treated with Intensity Modulation Radiated Therapy

Zou¹,

Song²,

Wang³

et al. 2014

Japanese Journal of Clinical Oncology

Self Cite

View full text Add to dashboard Cite

Objective: The incidence of radiation-induced late xerostomia varies greatly in nasopharyngeal carcinoma patients treated with radiotherapy. The single-nucleotide polymorphisms in genes involved in DNA repair and fibroblast proliferation may be correlated with such variability. The purpose of this paper was to evaluate the association between the risk of developing radiationinduced late xerostomia and four genetic polymorphisms: TGFb1 C-509T, TGFb1 T869C, XRCC3 722C.T and ATM 5557G.A in nasopharyngeal carcinoma patients treated with Intensity Modulation Radiated Therapy. Methods: The severity of late xerostomia was assessed using a patient self-reported validated xerostomia questionnaire. Polymerase chain reaction-ligation detection reaction methods were performed to determine individual genetic polymorphism. The development of radiationinduced xerostomia associated with genetic polymorphisms was modeled using Cox proportional hazards, accounting for equivalent uniform dose. Results: A total of 43 (41.7%) patients experienced radiation-induced late xerostomia. Univariate Cox proportional hazard analyses showed a higher risk of late xerostomia for patients with XRCC3 722 TT/CT alleles. In multivariate analysis adjusted for clinical and dosimetric factors, XRCC3 722C.T polymorphisms remained a significant factor for higher risk of late xerostomia. Conclusions: To our knowledge, this is the first study that demonstrated an association between genetic polymorphisms and the risk of radiation-induced late xerostomia in nasopharyngeal carcinoma patients treated with Intensity Modulation Radiated Therapy. Our findings suggest that the polymorphisms in XRCC3 are significantly associated with the risk of developing radiation-induced late xerostomia.

show abstract

Section: Patient Selectionmentioning

confidence: 99%

XRCC3 Polymorphisms are Associated with the Risk of Developing Radiation-induced Late Xerostomia in Nasopharyngeal Carcinoma Patients Treated with Intensity Modulation Radiated Therapy

Zou¹,

Song²,

Wang³

et al. 2014

Japanese Journal of Clinical Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Local control rates at 5 years have similarly improved from 60-70% to 85%. Preliminary reports of contemporary series treated with intensity-modulated RT (IMRT), based on shorter follow-up, showed even better results, with local control rates greater than 90% at 2 to 4 years and survival rates averaging 90% at 3 years (6)(7)(8)(9)(10)(11)(12)(13)(14). Similar impressive results were obtained in small series of patients treated in Phase II studies of induction CHT followed by concomitant chemoradiation (15,16) We previously reported on the improvement of outcome of NPC in a consecutive series of 171 patients treated at a single institution over a period of 10 years (1990-1999) (17).…”

Section: Introductionmentioning

confidence: 99%

Further Improvement in Outcomes of Nasopharyngeal Carcinoma With Optimized Radiotherapy and Induction Plus Concomitant Chemotherapy: An Update of the Milan Experience

Palazzi

Orlandi

Bossi

et al. 2009

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

“…Prescribing a dose per fraction (at least in some patients) higher than the one normally used may represent a limitation of our analysis. However, it should be noted that the use of dose per fraction .2.2 Gy (up to 2.5 Gy/fraction) has been repeatedly proposed and tested in the treatment of nasopharyngeal 38,39 and other head-neck carcinomas. 40,41 In addition, the use of high doses per fraction on the GTV simultaneously with the reduction of the dose to the SWOARs made it more challenging the possibility of achieving deep dose gradients.…”

Section: Discussionmentioning

confidence: 99%

Volumetric modulated arc therapy (VMAT) and simultaneous integrated boost in head-and-neck cancer: is there a place for critical swallowing structures dose sparing?

Cilla¹,

Deodato²,

Macchia³

et al. 2016

BJR

View full text Add to dashboard Cite

Simultaneous modulated accelerated radiation therapy in the treatment of nasopharyngeal cancer: A local center’s experience

Cited by 42 publications

References 22 publications

XRCC3 Polymorphisms are Associated with the Risk of Developing Radiation-induced Late Xerostomia in Nasopharyngeal Carcinoma Patients Treated with Intensity Modulation Radiated Therapy

XRCC3 Polymorphisms are Associated with the Risk of Developing Radiation-induced Late Xerostomia in Nasopharyngeal Carcinoma Patients Treated with Intensity Modulation Radiated Therapy

Further Improvement in Outcomes of Nasopharyngeal Carcinoma With Optimized Radiotherapy and Induction Plus Concomitant Chemotherapy: An Update of the Milan Experience

Volumetric modulated arc therapy (VMAT) and simultaneous integrated boost in head-and-neck cancer: is there a place for critical swallowing structures dose sparing?

Contact Info

Product

Resources

About